) recently decided to collaborate with
) for the commercialization of Dificid (fidaxomicin) tablets.
Dificid is indicated for the treatment of clostridium difficile
As per the terms of the agreement, AstraZeneca will be
responsible for the commercialization of Dificid in South America
including Brazil, Central America, Mexico and the Caribbean.
Optimer will be receiving an upfront payment of $1 million
along with up to $3 million in milestone payments on the first
commercial sale in some countries and up to $19 million on the
achievement of sales-related targets for Dificid in the specified
Optimer will also receive double-digit payments on net sales
in the collaboration territory, as per a supply agreement.
We remind investors that Dificid, Optimer's sole marketed
product, was launched in the US in July 2011 for treating
patients suffering from clostridium difficile-associated diarrhea
(CDAD), the most common form of nosocomial, or hospital acquired,
diarrhea. Dificid is also available in Canada. Moreover, Dificid
is approved in the European Union under the trade name,
The company has an exclusive two-year agreement (through July
) to co-promote Dificid in the US for the treatment of CDI.
Optimer also has an exclusive agreement with Astellas Pharma,
under which Astellas has the rights to develop and commercialize
Dificlir in Europe and certain other countries. In March 2012,
Optimer entered into another collaboration and license agreement
with Astellas Japan. Astellas was granted exclusive,
royalty-bearing license and intellectual property to develop and
commercialize Dificlir in Japan.
Currently, we have a Neutral stance on Optimer in the long
run. The company carries a Zacks #3 Rank (Hold) in the short
We are positive on Optimer's collaborative agreements for
Dificid. AstraZeneca with its global presence and marketing
experience should be a strong partner for Optimer. However, we
remain concerned about Optimer's dependence on a single product
ASTRAZENECA PLC (AZN): Free Stock Analysis
CUBIST PHARM (CBST): Free Stock Analysis
OPTIMER PHARMAC (OPTR): Free Stock Analysis
To read this article on Zacks.com click here.